empty
 
 
pl
Wyszukaj
Obsługa klienta
Szybkie założenie konta
Platforma handlowa
Wpłata/Wypłata
Wyszukaj
Dla Początkujących Dla Traderów Dla Partnerów Zrób sobie przerwę Informacje o InstaSpot
pl
#AUPH Return to the list of instruments #BGNE

Currency converter

AstraZeneca plc
157.49 USD
09 Sep 2026 19:58
Price Change (% chg)
$0.01
(0.01%)
Prev Close
Prev Close

Closing price, the previous day.
$159.98
Open
Open

Opening price.
$161.54
Day's High
Day's High

The highest price over the last trading day.
$159.98
Day's Low
Day's Low

The lowest price over the last trading day
$157.27
Week High
Week High

Price range high in the last week
$164.21
Week Low
Week Low

Price range low in the last week
$157.27
Download archive
Buy
157.52
Sell
157.49
Open the chart in full screen view
Buy
157.52
Sell
157.49
Download archive
Open the chart in full screen view

AstraZeneca PLC. About company

AstraZeneca PLC is one of the most well-known international companies in the industry. Its main research centers are located in several countries, including the UK, the US, and Sweden.

Notably, the company has been operating for more than 100 years. It was founded in 1913 in Sweden. Initially, the company was called Astra AB. However, it merged with Zeneca Group PLC in 1999, creating AstraZeneca PLC.

The company focuses on the development and commercialization of medicines against oncological, cardiovascular, inflammatory, and other diseases. In 2020, it developed a COVID-19 vaccine with funds received from the US Department of Health.

AstraZeneca's market capitalization stands at $127.68 billion. The company's revenue for 2021 amounted to $37.4 billion while the net profit was quite low, totaling $115 million.

AstraZeneca PLC. shares and factors impacting their price

AstraZeneca PLC shares are traded on the NASDAQ exchange under the AZN ticker.

Currently, AstraZeneca stock is estimated at $54-56. Over the past year, its price fluctuated in the range of $52.65 - $71.70.

You should pay attention to the following factors when trading its shares:

  • There are high risks associated with the production of a coronavirus vaccine. The company may completely abandon its creation;
  • Last year, AstraZeneca PLC. had to deal with a scandal over some side effects from the vaccine. Many countries refused to buy it;
  • AstraZeneca is mulling over the takeover of smaller companies involved in the treatment of cancer and other diseases;
  • The company's rating was upgraded from "hold" to "buy" in August 2022.

Nie możesz teraz rozmawiać przez telefon?
Zadaj pytanie na czacie.